References
- URL:http://www.alsuntangled.com/open.php. Accessed: 2016-09-18. (Archived by WebCite® at http://www.webcitation.org/6kcXed9qZ).
- URL:https://en.wikipedia.org/wiki/Serine. Accessed: 2016-09-18. (Archived by WebCite® at http://www.webcitation.org/6kcXiQ93z).
- Hawkins R, O’Kane R, Simpson I, Vina J. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 2006;136:2185–265.
- Banack S, Caller T, Stommel E. The cyanobacteria derived toxin beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis. Toxins 2010;2:2837–50.
- Dunlop R, Cox P, Banack S, Rodgers K. The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation. PLOS One 2013;8:e75376.
- Rochin J, Goto JJ, Competition of Beta-methylamino-L-alanine (BMAA) with Alanine and other Natural Amino Acids in Drosophila melanogaster. Society for the Advancement of Chicanos and Native Americans in Science (SACNAS) National Conference, Seattle, Washington, October 10-14, 2012.
- Rochin JL, Competition of beta-methylamino-L-alanine (BMAA) with alanine and other natural amino acids in Drosophila melanogaster, 245th Annual American Chemical Society meeting, New Orleans, Louisiana, April 7-11, 2013.
- Cox P, Davis D, Mash D, Metcalf J, Banack S. Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Prpc R Soc B 2015;283:2397.
- Snyder LR, Cruz-Aguado R, Sadilek M, Galasko D, Shaw CA, Montine TJ. Lack of cerebral bmaa in human cerebral cortex. Neurology 2009;72:1360–1.
- Berntzon L, Ronnevi L, Bergman B, Eriksson J. Detection of BMAA in the human central nervous system. Neuroscience 2015;292:137–47.
- Kirby G, Spencer P. Is Neurodegenerative disease a long-latency response to early-life genotoxin exposure? Int J Environ Res Public Health 2011;8:3889–921.
- Armon C. Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005-2015 update. Muscle Nerve 2016;53:842–9.
- Phillips T, Rothstein J. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol 2015;69:1–21.
- Sances S, Bruijn L, Chandran S, Eggan K, Ho R, Klim J, et al. Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat Neurosci 2016;19:542–53.
- Karamayan V, Speth R. Animal models of BMAA neurotoxicity: a critical review. Life Sciences 2008;82:233–46.
- Purdie EL, Samsudin S, Eddy FB, Codd GA. Effects of the cyanobacterial neurotoxin beta-N-methylamino-L-alanine on the early-life stage development of zebrafish (Danio rerio). Aquatic Toxicology (Amsterdam, Netherlands) 2009;95:279–84.
- Zhou X, Escala W, Papapetropoulos S, Zhai RG. β-N-methylamino-L-alanine induces neurological deficits and shortened life span in Drosophila. Toxins 2010;2:2663–79.
- Karlsson O, Berg AL, Lindstrom AK, Hanrieder J, Arnerup G, Roman E, et al. Neonatal exposure to the cyanobacterial toxin BMAA induces changes in protein expression and neurodegeneration in adult hippocampus. Toxicological Sciences: An Official Journal of the Society of Toxicology 2012;130:391–404.
- Karlsson O, Kultima K, Wadensten H, Nilsson A, Roman E, Andren PE, et al. Neurotoxin-induced neuropeptide perturbations in striatum of neonatal rats. Journal of Proteome Research 2013;12:1678–90.
- Karlsson O, Bergquist J, Andersson M. Quality measures of imaging mass spectrometry aids in revealing long-term striatal protein changes induced by neonatal exposure to the cyanobacterial toxin beta-N-methylamino-L-alanine (BMAA). Molecular & Cellular Proteomics: MCP 2014;13:93–104.
- Karlsson O, Jiang L, Andersson M, Ilag LL, Brittebo EB. Protein association of the neurotoxin and non-protein amino acid BMAA (beta-N-methylamino-l-alanine) in the liver and brain following neonatal administration in rats. Toxicology Letters 2014;226:1–5.
- de Munck E, Munoz-Saez E, Antonio MT, Pineda J, Herrera A, Miguel BG, et al. Effect of β-N-methylamino-L-alanine on oxidative stress of liver and kidney in rat. Environmental Toxicology and Pharmacology 2013;35:193–9.
- Przedborski S. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist 2004;10:1–7.
- Parakh S, Atkin J. Protein folding alterations in amyotrophic lateral sclerosis. Brain Res 2016;1648:633–649.
- URL:https://www.patientslikeme.com/treatments/show/9413-lserine-side-effects-and-efficacy#overview. Accessed: 2016-09-18. (Archived by WebCite® at http://www.webcitation.org/6kcY86zK1).
- URL:http://www.alsforums.com/forum/general-discussion-about-als-mnd/25976-l-serine-5.html. Accessed: 2016-09-18. (Archived by WebCite® at http://www.webcitation.org/6kcYNVzuq).
- URL:http://www.alstdi.org/forum/yaf_postst55397_supplement-with-lserine.aspx. Accessed: 2016-09-18. (Archived by WebCite® at http://www.webcitation.org/6kcYRpywD).
- Levine T, Miller R, Bradley W, Moore D, Saperstein D, Flynn L, et. al. Phase 1 clinical safety of L-serine for ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2016 [Epub ahead of print].
- Gordon P, Moore D, Miller R, Florence J, Verheijde J, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol 2007;6:1045–53.
- URL:http://www.jomarlabs.com/amino-acids/l-serine.html. Accessed: 2016-10-12. (Archived by WebCite® at http://www.webcitation.org/6lCjaagq6).